Arcus Biosciences, Inc.

Company Overview We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients. The chart below summarizes our current clinical and late pre-clinical stage portfolio: * Taiho holds exclusive licenses in Japan and certain other Asian countries, excluding China, for casdatifan (the Taiho Territory ). Gilead and Arcus co-develop globally and share co-promotion rights in the U.S. for domvanalimab and quemliclustat. Gilead holds commercialization rights outside of the U.S. subject to Taiho’s rights for the Taiho Territory. Gilead has certain option rights as further described under Licenses and Collaborations . 1 Table of Contents Oncology Programs Casdatifan (HIF-2 Inhibitor) Casdatifan is our oral, small-molecule inhibitor of HIF-2 , a target that has been commercially validated by the approval of Merck & Co., Inc's ("Merck") HIF-2 inhibitor belzutifan. HIF-2 is a protein that is involved in sensing oxygen availability in multiple organs.